Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

PI3Kα inhibitors: Addressing unmet needs through precision medicine in HR+, HER2- ABC - From scientific breakthrough to clinical practice (ID 353)

Lecture Time
19:30 - 19:40
Speakers
  • P. Aftimos (Brussels, Belgium)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00